Introduction of Claude for Life Sciences: Anthropic has launched Claude for Life Sciences, an AI tool designed to assist researchers throughout the scientific discovery process, from literature reviews to regulatory submissions, marking the company's first formal entry into the life sciences sector.
Integration and Partnerships: The new offering integrates with key scientific tools and partners with organizations like Benchling and cloud providers to enhance AI adoption in life sciences, aiming to improve efficiency in research while acknowledging the inherent limitations of scientific processes.
TXG
$15.45+Infinity%1D
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 15.460
Low
9.00
Averages
13.00
High
18.00
Current: 15.460
Low
9.00
Averages
13.00
High
18.00
Barclays
NULL
to
Overweight
maintain
$17 -> $22
2025-12-15
New
Reason
Barclays
Price Target
$17 -> $22
2025-12-15
New
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on 10x Genomics to $22 from $17 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Citi
Buy -> Neutral
downgrade
$18
2025-12-11
New
Reason
Citi
Price Target
$18
2025-12-11
New
downgrade
Buy -> Neutral
Reason
Citi downgraded 10x Genomics to Neutral from Buy with an unchanged price target of $18. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. Citi cites cautious customer spending in 10x's academic and government end markets, an uncertain biotech recovery timing, ramping competition, and a balanced risk/reward post the recent rally for the downgrade.
Piper Sandler
Neutral
maintain
$15 -> $19
2025-11-11
Reason
Piper Sandler
Price Target
$15 -> $19
2025-11-11
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on 10x Genomics to $19 from $15 and keeps a Neutral rating on the shares. The firm cites the company's quarterly results for the price target change.
Canaccord
Buy
maintain
$16 -> $19
2025-11-07
Reason
Canaccord
Price Target
$16 -> $19
2025-11-07
maintain
Buy
Reason
Canaccord raised the firm's price target on 10x Genomics to $19 from $16 and keeps a Buy rating on the shares. The firm said TXG remains one their top picks in Tools after a solid 3Q25, as they are optimistic that the company can reaccelerate growth in the relative near term.
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
